title: Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy.
abstract: Noscapine is an antitussive and potential anticancer drug. Clinically significant interactions between warfarin and noscapine have been previously reported. In this study, to provide a basis for warfarin dosage adjustment, the inhibition kinetics of noscapine against warfarin metabolism was characterized. Our enzyme kinetics data obtained from human liver microsomes and recombinant CYP2C9 proteins indicate that noscapine is a competitive inhibitor of the (S)-warfarin 7-hydroxylation reaction by CYP2C9. Interestingly, noscapine also inhibited (S)-warfarin metabolism in a NADPH- and time-dependent manner, and removal of unbound noscapine and its metabolites by ultrafiltration did not reverse inhibition of (S)-warfarin metabolism by noscapine, suggesting mechanism-based inhibition of CYP2C9 by noscapine. Spectral scanning of the reaction between CYP2C9 and noscapine revealed the formation of an absorption spectrum at 458 nm, indicating the formation of a metabolite-intermediate complex. Surprisingly, noscapine is a 2- to 3-fold more efficient inactivator of CYP2C9.2 and CYP2C9.3 variants than it is of the wild type, by unknown mechanisms. Based on the inhibitory kinetic data, (S)-warfarin exposure is predicted to increase up to 7-fold (depending on CYP2C9 genotypes) upon noscapine coadministration, mainly due to mechanism-based inactivation of CYP2C9 by noscapine. Together, these results indicate that mechanism-based inhibition of CYP2C9 by noscapine may dramatically alter pharmacokinetics of warfarin and provide a basis for warfarin dosage adjustment when noscapine is coadministered.
authors.affiliation: Department of Medicinal Chemistry and Pharmacognosy (N.Z.), Department of Pharmacy Practice (Y.-Y.Z., H.J.), and Department of Biopharmaceutical Sciences (H.J.), College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois; and Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, Washington (R.P.S., K.L.K.).
authors.forename: Nan
authors.initials: N
authors.lastname: Zhang
authors.forename: Ryan P
authors.initials: RP
authors.lastname: Seguin
authors.forename: Kent L
authors.initials: KL
authors.lastname: Kunze
authors.forename: Yan-Yan
authors.initials: YY
authors.lastname: Zhang
authors.forename: Hyunyoung
authors.initials: H
authors.lastname: Jeong
mesh_terms: D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors / Q000378:metabolism; D065729:Cytochrome P-450 CYP2C9; D004347:Drug Interactions / Q000502:physiology; D006801:Humans; D006900:Hydroxylation / Q000502:physiology*; D007700:Kinetics; D008862:Microsomes, Liver / Q000201:enzymology / Q000378:metabolism; D009665:Noscapine / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000378:metabolism; D014859:Warfarin / Q000378:metabolism* / Q000493:pharmacokinetics*
chemical_list: D011994:Recombinant Proteins; D014859:Warfarin; D009665:Noscapine; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases
references.citation: Clin Pharmacokinet. 2013 Mar;52(3):199-209
references.pmid: 23344982
references.citation: Drug Metab Dispos. 2007 Feb;35(2):246-55
references.pmid: 17093004
references.citation: Br J Clin Pharmacol. 2013 Jan;75(1):208-16
references.pmid: 22616655
references.citation: Clin Pharmacol Ther. 2002 Dec;72(6):702-10
references.pmid: 12496751
references.citation: Drug Metab Dispos. 2009 Jul;37(7):1355-70
references.pmid: 19359406
references.citation: Xenobiotica. 1971 Nov;1(6):581-91
references.pmid: 4154538
references.citation: Clin Pharmacol Ther. 2012 Apr;91(4):660-5
references.pmid: 22378156
references.citation: Anticancer Res. 2010 Feb;30(2):399-401
references.pmid: 20332445
references.citation: Chem Res Toxicol. 1992 Jan-Feb;5(1):54-9
references.pmid: 1581537
references.citation: Eur J Clin Pharmacol. 1986;31(3):367-9
references.pmid: 3792437
references.citation: Biochem Pharmacol. 1988 May 15;37(10):1981-90
references.pmid: 3377806
references.citation: PLoS One. 2011 Mar 15;6(3):e17733
references.pmid: 21423660
references.citation: Xenobiotica. 1981 Jan;11(1):23-32
references.pmid: 7222727
references.citation: Eur J Clin Pharmacol. 1986;30(2):213-5
references.pmid: 3709649
references.citation: Br J Clin Pharmacol. 2010 Feb;69(2):193-9
references.pmid: 20233183
references.citation: Clin Pharmacol Ther. 2010 Sep;88(3):343-6
references.pmid: 20668444
references.citation: Expert Opin Drug Metab Toxicol. 2007 Jun;3(3):321-9
references.pmid: 17539741
references.citation: J Biol Chem. 1964 Jul;239:2370-8
references.pmid: 14209971
references.citation: Drug Metab Dispos. 2009 Jan;37(1):59-65
references.pmid: 18838506
references.citation: Drug Metab Dispos. 2008 Jul;36(7):1242-8
references.pmid: 18378563
references.citation: Nature. 2003 Jul 24;424(6947):464-8
references.pmid: 12861225
references.citation: Drug Metab Dispos. 1996 Apr;24(4):429-35
references.pmid: 8801058
references.citation: J Pharm Pharmacol. 1990 Feb;42(2):140-3
references.pmid: 1972403
references.citation: Ann Pharmacother. 2008 Mar;42(3):448-50
references.pmid: 18303135
references.citation: Drug Metab Dispos. 2006 Dec;34(12):1966-75
references.pmid: 16963489
references.citation: Br J Pharmacol. 2012 Nov;167(6):1271-86
references.pmid: 22671862
references.citation: Drug Metab Dispos. 1999 Feb;27(2):180-7
references.pmid: 9929500
references.citation: Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):92-7
references.pmid: 19149691
references.citation: Thromb Res. 2013 Mar;131(3):210-7
references.pmid: 23290095
references.citation: J Biol Chem. 2004 Aug 20;279(34):35630-7
references.pmid: 15181000
references.citation: Anticancer Drugs. 2011 Jul;22(6):543-55
references.pmid: 21471809
references.citation: Drug Metab Dispos. 1996 Apr;24(4):414-21
references.pmid: 8801056
references.citation: Br J Clin Pharmacol. 2008 Feb;65(2):277-8
references.pmid: 17875192
references.citation: Br J Clin Pharmacol. 2005 Nov;60(5):508-18
references.pmid: 16236041
references.citation: Drug Metab Dispos. 2009 Sep;37(9):1895-903
references.pmid: 19541829
references.citation: J Clin Oncol. 2009 Oct 10;27(29):4889-94
references.pmid: 19738109
references.citation: J Med Chem. 2012 Jun 14;55(11):4896-933
references.pmid: 22409598
references.citation: Pharmacogenomics. 2012 Mar;13(4):429-40
references.pmid: 22379999
references.citation: Drug Metab Dispos. 2012 Sep;40(9):1653-7
references.pmid: 22685217
references.citation: Lung Cancer. 2011 Mar;71(3):271-82
references.pmid: 20674069
references.citation: Cancer Chemother Pharmacol. 2007 Nov;60(6):831-9
references.pmid: 17285314
references.citation: J Clin Oncol. 2009 Oct 10;27(29):4895-901
references.pmid: 19738121
references.citation: Tidsskr Nor Laegeforen. 2009 Mar 12;129(6):540
references.pmid: 19282895
references.citation: Drug Metab Dispos. 2005 Jun;33(6):837-44
references.pmid: 15897600
references.citation: Eur J Clin Pharmacol. 1990;39(3):275-9
references.pmid: 2257866
references.citation: Chest. 2001 Jan;119(1 Suppl):8S-21S
references.pmid: 11157640